Monday, October 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 27, 2026

AstraZeneca results: H1 and Q2 2026

View original at finance.yahoo.com
AstraZeneca results: H1 and Q2 2026 Growth momentum continues…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AstraZeneca saw strong H1 2026 performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including US approval of Baxfendy for hypertension.

    60% confidence

  • If FX rates from July-December 2026 remain at June 2026 average levels, FY2026 Total Revenue would see a low single-digit percentage positive benefit versus CER performance, and Core EPS growth would be broadly similar to CER growth.

    60% confidence

  • Core EPS for FY 2026 is expected to increase by a low double-digit percentage at CER.

    60% confidence

  • The Core Tax rate is expected to be between 18-22% for FY 2026.

    60% confidence

  • Despite disappointment over the CARDIO-TTRansform trial outcome, AstraZeneca remains on track for its $80bn Total Revenue ambition and is confident in its pipeline, with more than twenty high-value readouts due over the next 18 months.

    60% confidence

  • AstraZeneca continues to invest in transformative technologies and commercial execution to drive growth beyond 2030.

    60% confidence

  • Total Revenue for FY 2026 is expected to increase by a mid-to-high single-digit percentage at CER.

    60% confidence

Data points we hold from this source

AstraZeneca AB · revenue30595 USD
AstraZeneca AB · eps1.61 USD
AstraZeneca AB · dividend per share1.06 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,371 source documents archived
Query this data → isubstrate.com
AstraZeneca results: H1 and Q2 2026 — Source | Via News | Via News